Curative Biotechnology, Inc.
CUBT
Rank in Stocks
#30219
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused... Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
Share Price
$0.83
Last synced: 2026-11-09
Market Cap
$5.66M
Change (1 day)
0.00%
Change (1 year)
-11.04%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Curative Biotechnology, Inc. (CUBT)
Category
Healthcare
Operating Margin for Curative Biotechnology, Inc. (CUBT)
Operating Margin as of November 2026 TTM: 0.00%
According to Curative Biotechnology, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Curative Biotechnology, Inc. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -13.69% | -82.21% |
| 2015 | -76.94% | 78.47% |
| 2014 | -43.11% | 255.99% |
| 2013 | -12.11% | -94.31% |
| 2012 | -212.69% | -26.58% |
| 2011 | -289.70% | -63.17% |
| 2010 | -786.65% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Curative Biotechnology, Inc.'s operating margin
What was Curative Biotechnology, Inc.'s operating margin in 2025?
In 2025, Curative Biotechnology, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Curative Biotechnology, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Curative Biotechnology, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Curative Biotechnology, Inc.'s operating margin compare with similar companies?
Curative Biotechnology, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.